Brief: Roche Canada & PCPA Complete Negotiations For Perjeta For Neoadjuvant Treatment Of Early Stage Breast Cancer
18/08/2026 15:43
BRIEF-Roche Canada & PCPA Complete Negotiations For Perjeta For Neoadjuvant Treatment Of Early Stage Breast Cancer Aug 18 (Reuters) - Roche Canada:
ROCHE CANADA AND THE PAN-CANADIAN PHARMACEUTICAL ALLIANCE (PCPA) SUCCESSFULLY COMPLETE NEGOTIATIONS FOR PERJETA® (PERTUZUMAB) FOR THE NEOADJUVANT TREATMENT OF AGGRESSIVE EARLY STAGE BREAST CANCER
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Roche Holding AG
See all newsNovartis presents weaker-than-expected relapse data for multiple sclerosis drug remibrutinib
Brief: Roche Says Sefaxersen Achieved Statistically Significant 43.1% Reduction In Proteinuria In Interim Phase III Data
Brief: Zymeworks Signs Exclusive Global Licensing Deal With Roche For Cancer Drug ZW209
Zymeworks licenses experimental lung cancer drug to Roche in up to $813 million deal
DB ups Roche to 'buy' on positive oncology survey